Stage
No active trials
Next date
None yet
Trials
0 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acne Vulgaris on the Face
- Main trialPhase 2
- “Double blinded, randomized, placebo-controlled trial to determine the safety and efficacy of topical AT-004 therapy in participants with acne vulgaris, including assessment of reduction in the number of acne lesions and IGA. A PK sub-study will be performed in a subset of participants. Participants with moderate to severe acne vulgaris, aged 18 to 45 years, who are likely to meet inclusion and none of the exclusion criteria will be invited for a screening visit. The study include a screening period, treatment phase with the baseline visit at day 1 and a follow -up visits at week 4, 8 and week…”In the company’s words, NCT07774364 on ClinicalTrials.gov
Other drugs for Acne Vulgaris on the Face
- TrifaroteneGalderma R&D · Phase 3
- Cyproterone Acetate and Ethinyl EstradiolEurofarma Laboratorios S.A. · Phase 3
- DenifanstatSagimet Biosciences Inc. · Ascletis · Phase 3
- ClascoteroneZhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Phase 3
- B244AOBiome LLC · Phase 2
- Acne mRNA vaccineSanofi · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 15 Jul 2026 | Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026